Objective To develop practical recommendations for the use of low-molecular-weight
heparins (LMWHs) as prophylaxis and treatment of venous thromboembolism and acute …

This chapter about antithrombotic therapy in native and prosthetic valvular heart disease is
part of the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy …

This chapter about antithrombotic therapy for valvular heart disease is part of the American
College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) …

Aims There have been no large observational studies attempting to identify predictors of
major bleeding in patients with acute coronary syndromes (ACS), particularly from a …

Therapeutic options for the management of venous thromboembolism (VTE) in patients with
cancer remain very limited. Although low-molecular-weight heparin monotherapy has been …

Background: Deep venous thromboses (DVT) continue to cause significant morbidity in
critically ill patients. Standard prophylaxis for high risk patients includes twice-daily dosing …

Venous thromboembolism and adverse pregnancy outcomes are potential complications of
pregnancy. Numerous studies have evaluated both the risk factors for and the prevention …

Objectives The objective of this study was to compare the pharmacokinetics of the low
molecularweight heparin enoxaparin in obese and nonobese volunteers, by means of two …

INTRODUCTION: In clinical trials, fixed-dose enoxaparin (40 mg once daily) reduces the risk
of venous thromboembolism (VTE) in medically-ill patients. However, morbidly obese …

Background: Obesity is considered a highly prevalent risk factor for venous
thromboembolism (VTE) in hospitalized patients. However, recommendations for VTE …